Lene Hammer-Helmich

Lundbeck

H指数:14

被引数:838

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular genetic influences on sustained attention and executive processes and their links with psychopathology in the AFFECT study

AFFECT研究中分子遗传因素对持续性注意力和执行功能的影响及其与精神病理学的关联

Molecular Psychiatry

IF10.1

2026-07-070

OAAI

HEAD-WINd ^® : A nationwide cohort study of headache disorders in danish adults using survey, smartphone and registry data

逆风 <sup>®</sup> : 一项使用调查、智能手机和注册数据对丹麦成年人头痛疾病进行的全国性队列研究

Cephalalgia

IF4.6

2026-01-280

PRE

GENETIC ARCHITECTURE OF COMPLEX COGNITIVE PROCESSES AND LINKS TO PSYCHOPATHOLOGY

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2023-10-010

PRE

Burden of Medication Overuse in Migraine: A Cross-sectional, Population-Based Study in Five European Countries Using the 2020 National Health and Wellness Survey (NHWS)

偏头痛药物过度使用的负担: 使用2020国家健康与健康调查 (NHWS) 在五个欧洲国家进行的一项基于人群的横断面研究

NEUROLOGY AND THERAPY

IF4.8

2023-09-202

OAAI

Characterizing mood disorders in the AFFECT study: a large, longitudinal, and phenotypically rich genetic cohort in the US

TRANSLATIONAL PSYCHIATRY

IF6.2

2022-03-257

OAAI

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

在现实世界的临床实践中，沃替西汀对重度抑郁症患者的有效性: reval研究的结果

FRONTIERS IN PSYCHIATRY

IF3.2

2022-03-0924

OAAI

Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder

通过抑郁症状对重度抑郁症患者抗抑郁药治疗的早期反应来预测残留的认知障碍

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2022-01-015

OAAI

Effectiveness and safety of vortioxetine in real-world clinical practice in China: results from the prospective RELIEVE China study

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-12-010

PRE

Vortioxetine in routine clinical practice: results from the real-life effectiveness of vortioxetine (RELIEVE) study

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-12-012

PRE

Effectiveness of vortioxetine in real-world clinical practice: Interim results from the relieve study

EUROPEAN PSYCHIATRY

IF6.7

2021-08-131

OAAI

Improvement in functioning after treatment of major depression with vortioxetine. interim results from the real-life effectiveness of vortioxetine (RELIEVE) study

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2019-12-010

PREAI

Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2019-11-0146

OAAI

QUALITY OF LIFE AND HEALTHCARE RESOURCE USE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN CHINA: RESULTS FROM THE PROACT STUDY

VALUE IN HEALTH

IF6

2018-09-010

OAAI

Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study

BMC PSYCHIATRY

IF3.6

2018-03-275

OAAI

Depression severity and cognitive symptoms are independent predictors of functioning in patients with depression

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2017-10-012

PREAI

Health service use among children with and without eczema, asthma, and hay fever

有和没有湿疹，哮喘和干草发热的儿童的卫生服务使用

clinical epidemiology

IF3.2

2016-09-0111

OAAI

DEVELOPMENT OF A TOLERABILITY BURDEN INDEX IN SCHIZOPHRENIA: MOVING ADVERSE EVENT REPORTING TOWARD PATIENTS' PERSPECTIVES IN CLINICAL TRIALS

VALUE IN HEALTH

IF6

2016-05-010

OAAI

Atopy and cause-specific mortality

CLINICAL AND EXPERIMENTAL ALLERGY

IF5.2

2014-10-2115

PREAI

Social disparities in children's exposure to second hand smoke at home: a repeated cross-sectional survey

ENVIRONMENTAL HEALTH

IF5.9

2012-09-1751

OAAI

Lene Hammer-Helmich

个人简介

教育背景

工作经历

荣誉奖项

研究方向